Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Immunovaccine Inc. (OTC: IMMVF).

Full DD Report for IMMVF

You must become a subscriber to view this report.


Recent News from (OTC: IMMVF)

Immunovaccine Shareholders Approve Share Consolidation at 99.85%
HALIFAX, Nova Scotia, May 01, 2018 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX:IMV)(OTCQX:IMMVF), a clinical stage immuno-oncology corporation, today announced that at the annual and special meeting of shareholders held on May 1, 2018, the share consolidation as described in the management ...
Source: GlobeNewswire
Date: May, 01 2018 16:35
Stonegate Capital Partners Initiates Coverage on ImmunoVaccine, Inc. (TSX: IMV)
DALLAS, TX / ACCESSWIRE / April 30, 2018 / Stonegate Capital Partners has initiated research coverage on ImmunoVaccine, Inc. (TSX: IMV) (OTCQX: IMMVF). Despite ongoing advancements in the development of cancer treatment, pharmaceutical developers are still facing challenges involved with...
Source: ACCESSWIRE
Date: April, 30 2018 16:30
Immunovaccine to Highlight Clinical Data for Its Lead Candidate in Oral Presentation at 54th Annual Meeting of the American Society of Clinical Oncology
HALIFAX, Nova Scotia, April 26, 2018 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncology company, today announced that its abstract has been selected for an oral presentation at the upcoming 2018 American Society of Clinical Oncology (ASCO) Annua...
Source: GlobeNewswire
Date: April, 26 2018 07:05
Immunovaccine and Incyte Expand Clinical Collaboration Evaluating Combination Immunotherapies in Advanced Recurrent Ovarian Cancer
HALIFAX, Nova Scotia, April 24, 2018 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncology company, today announced that it has entered into an agreement with Incyte Corporation to expand their ongoing clinical trial collaboration. The Companies pl...
Source: GlobeNewswire
Date: April, 24 2018 07:05
Immunovaccine Announces Leading Independent Proxy Advisory Firms Recommend Voting for Share Consolidation Related to Potential Nasdaq Listing
HALIFAX, Nova Scotia, April 17, 2018 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncology corporation, is pleased to announce that Institutional Shareholder Services Inc. (“ISS”) and Glass, Lewis & Co., LLC (“Glass Lewis&#...
Source: GlobeNewswire
Date: April, 17 2018 07:05
New Preclinical Studies Reinforce the Potential for Heightened Anti-Cancer Activity of Combination Therapies Based on Immunovaccine's Proprietary Delivery Platform
HALIFAX, Nova Scotia, April 16, 2018 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncology company, today announced that it presented new research on its T-cell activating platform at the American Association for Cancer Research (AACR) Annual Meet...
Source: GlobeNewswire
Date: April, 16 2018 09:05
Immunovaccine (IMMVF) Investor Presentation - Slideshow
The following slide deck was published by Immunovaccine Inc. in conjunction with this Read more ...
Source: SeekingAlpha
Date: April, 11 2018 13:25
Immunovaccine Files Circular for Annual and Special Meeting of Shareholders
NOT FOR DISTRIBUTION TO THE U.S. NEWSWIRE OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, April 04, 2018 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncology corporation, is pleased to announce that it has filed its management in...
Source: GlobeNewswire
Date: April, 04 2018 16:05
Immunovaccine initiates patient dosing in Phase 2 clinical trial of DPX-Survivac in combination with pembrolizumab in patients with DLBCL
Immunovaccine ( OTCQX:IMMVF ) announces that the first patient has been treated in a Phase 2 Study combining DPX-Survivac with Low Dose Cyclophosphamide administered with Pembrolizumab in patients with persistent or recurrent/refractory Diffuse Large B-Cell Lymphoma (DLBCL). More n...
Source: SeekingAlpha
Date: March, 28 2018 08:47
Immunovaccine Announces Initiation of Patient Dosing in Investigator-Sponsored Phase 2 Clinical Trial of Its Lead Candidate DPX-Survivac Used in Combination with Pembrolizumab in Patients with DLBCL
HALIFAX, Nova Scotia, March 28, 2018 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncology company, today announced that the first patient has been treated in a Phase 2 Study combining DPX-Survivac with Low Dose Cyclophosphamide administered with P...
Source: GlobeNewswire
Date: March, 28 2018 07:05

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-101.601.66891.66891.58374,800
2018-05-091.601.66891.66891.58374,800
2018-05-081.741.60351.741.593116,864
2018-05-021.541.54531.54531.542,000
2018-05-011.58551.55281.58591.544520,640

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-095004,80010.4167Cover
2018-05-071,10016,5106.6626Cover
2018-05-046,70016,30441.0942Short
2018-05-036421,8380.2931Cover
2018-05-0120020,6400.9690Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on IMMVF.


About Immunovaccine Inc. (OTC: IMMVF)

Logo for Immunovaccine Inc. (OTC: IMMVF)

Immunovaccine Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and infectious diseases. ImmunoVaccine is developing T cell activating cancer immunotherapies based on its patented immuno stimulating technology platform, which provides controlled and prolonged delivery of immuno stimulating agents to the immune system. ImmunoVaccine has advanced two T cell activation therapies for cancer through phase human clinical trials, and is currently conducting a phase b with Incyte Corp. and a phase study with Merck as a combination therapies in ovarian cancer. The Corporation also have an ongoing combination trial in diffuse large B cell lymphoma with Merck. These studies assessing lead candidate, DPX Survivac. The Company is also advancing an infectious disease pipeline including innovative vaccines for respiratory syncytial virus RSV , and currently has clinical projects ongoing to assess the potential of DepoVax to address malaria and the Zika virus. Connect at www.imvaccine.com.

 

 

 

Current Management

  • Fred Ors / CEO
  • Pierre Labbe / CFO
  • Gabriela Rosu / Chief Med. Officer
  • Brittany Davison / Director, Fin.
  • Andrew Sheldon / Chairman, Independent Director, Audit Committee Member, Compensation Committee Member, Nominating Committee Member
  • Wade Dawe / Independent Director, Compensation Committee Member, Nominating Committee Member
  • Wayne Pisano / Independent Director, Audit Committee Member, Compensation Committee Member, Nominating Committee Member
  • Albert Scardino / Independent Director, Compensation Committee Member, Nominating Committee Member
  • Alfred Smithers / Independent Director
  • Shermaine Tilley / Independent Director, Audit Committee Member

Current Share Structure

  • Market Cap: $199,986,842 - 03/09/2018
  • Issue and Outstanding: 129,023,769 - 12/31/2017
  • Float: 96,837,102 - 12/31/2017

 


Recent Filings from (OTC: IMMVF)

Management Discussion and Analysis - Management Discussion and Analysis Q3F2017
Filing Type: Management Discussion and Analysis - Management Discussion and Analysis Q3F2017Filing Source: OTC Markets
Filing Date: November, 09 2017
Interim Financial Report - Interim Financial Statements Q3F2017
Filing Type: Interim Financial Report - Interim Financial Statements Q3F2017Filing Source: OTC Markets
Filing Date: November, 09 2017
Interim Financial Report - Unaudited Interim Financial Statements Q2 F2017
Filing Type: Interim Financial Report - Unaudited Interim Financial Statements Q2 F2017Filing Source: OTC Markets
Filing Date: August, 09 2017
Quarterly Report - Management Discussion & Analysis - Q2 F2017
Filing Type: Quarterly Report - Management Discussion & Analysis - Q2 F2017Filing Source: OTC Markets
Filing Date: August, 09 2017
Interim Financial Report - Q1 2017 Interim Financial Statements
Filing Type: Interim Financial Report - Q1 2017 Interim Financial StatementsFiling Source: OTC Markets
Filing Date: May, 10 2017
Management Discussion and Analysis - Q1 2017 Management Discussion and Analysis
Filing Type: Management Discussion and Analysis - Q1 2017 Management Discussion and AnalysisFiling Source: OTC Markets
Filing Date: May, 10 2017
Management Discussion and Analysis - Management Discussion and Analysis
Filing Type: Management Discussion and Analysis - Management Discussion and AnalysisFiling Source: OTC Markets
Filing Date: March, 30 2017
Annual Report - Annual Financial Statements
Filing Type: Annual Report - Annual Financial StatementsFiling Source: OTC Markets
Filing Date: March, 30 2017
Supplemental Information - Annual Information Form
Filing Type: Supplemental Information - Annual Information FormFiling Source: OTC Markets
Filing Date: March, 30 2017
Management Discussion and Analysis - Q3 2016 Management Discussion and Analysis
Filing Type: Management Discussion and Analysis - Q3 2016 Management Discussion and AnalysisFiling Source: OTC Markets
Filing Date: November, 08 2016

 

 


Daily Technical Chart for (OTC: IMMVF)

Daily Technical Chart for (OTC: IMMVF)


Stay tuned for daily updates and more on (OTC: IMMVF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: IMMVF)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in IMMVF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of IMMVF and does not buy, sell, or trade any shares of IMMVF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/